The researchers conducted a study with 5000 people on the incidence of heart disease. The analysis was performed by observing the effects of air pollution on the blood pressure between 2000 and 2003.
“Air pollution is not only a trigger for heart attacks and strokes, but also influence the occurrence of the disease process,” said Dr. Barbara Hoffmann, the lead researcher.
High blood pressure is a risk factor ateroklerosis or hardening of the blood vessels that lead to heart disease and stroke. From previous studies have found that increased air pollution, blood pressure is increased, but long-term effect is unknown.
Malignant peritoneal mesothelioma is a rare form of cancer that develops in the thin cell walls that surround the abdominal cavity, called the peritoneum. Other types of cancer, including mesothelioma malignant pleural mesothelioma, which occurs in the cell wall that surrounds the lungs and malignant pericardial mesothelioma, which occurs in the pericardial wall of the house. peritoneal mesothelioma is the rarest form, the second of the disease and accounts for approximately 20% of cases of mesothelioma each year.
What causes peritoneal mesothelioma?
Peritoneal mesothelioma is known to be caused by exposure to asbestos. Asbestos is said to reach the abdominal wall by one of two methods. The first is through the ingestion of asbestos fibers that are processed by digestion and stay in the peritoneum. The other method is through the lungs and lymph nodes by inhaled asbestos fibers. Malignant pleural mesothelioma is also known to metastasize directly into the abdominal cavity, if disclosure is not slower.
The natural protein is known to play an important role in promoting cell death (for example in mammary cells after the young are weaned), prevention of cell proliferation, promoting cell differentiation, and in this new discovery, by blocking the formation of blood vessels.
The trial results, published in the American Journal of Pathology showed that the protein – related protein secreted curly 4 (sFRP4) – inhibits tumors in the same degree as a very successful antibody, Avastin ®.
Winthrop Professor Arun Dharmaraj UWA School of Anatomy and Human Biology and UWA, said Anna University (AU), Chennai, India, holders of patents on the use of sFRP4 as angiogenesis inhibitor and are eager to find a trading partner for project.
A better understanding of Skp2 gene and its relation to cellular senescence can lead to the development of new agents that can suppress tumor growth in certain types of cancer, researchers at the University of Texas, MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature. Journal Skp2 is involved in promoting cell cycle regulation, cell proliferation, cell growth and tumor formation, and is overexpressed in a variety of human cancers, according to lead author Hui-Kuan Lin, Ph.D., professor MD Anderson Cancer assistant molecular and cell biology.
Lin and colleagues found that inactivation oncogenes are overexpressed Skp2 after strangling cancer growth by inducing senescence – the irreversible loss of the ability of a cell to divide and grow. Harnessing the power of cellular senescence to push rapidly dividing cells in a dormant state could provide an alternative means of prevention or control of the common malignant tumors such as prostate cancer.
The reduction or no fill “for ECG triggered coronary CT angiography (CTA) results in a substantial reduction in radiation doses without compromising image quality and performance, according to a study published in the April edition in American Journal of Radiology. ECG triggered coronary CTA is a common, minimally invasive procedure used to evaluate blockages in the coronary arteries.
“During ECG-triggered coronary CTA, there is a mandatory minimum that the scanner should be the course of each heartbeat, and there is usually an extension was added before and after what is called” filler, “said Troy LaBounty , MD, lead study author. ” By reducing or eliminating the filler that shorten the scanning time and reduce the dose of radiation, “LaBounty said.
The study was conducted at three sites, including Weill Cornell Medical College in New York, NY Radiology Associates Fairfax in Fairfax, Virginia and the University of British Columbia in Vancouver, Canada. We included 886 patients who underwent ECG-triggered coronary CTA with a time of filling 0, 1-99, 100-150 or milliseconds.
About 40 percent of children and up to 70 percent of adults in remission from Acute Myeloid Leukemia (AML) will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, constantly replicating cancer cells that produce immature blood cells characteristic of leukemia and are resistant to traditional cancer treatments. Now, researchers at Children’s Hospital Boston have discovered a possible way to kill these cells and prevent the release of a relapse.The study, published online March 26 in the journal Science, shows that leukemic stem cells can not thrive without a particular cellular pathway, known as the Wnt / beta-catenin, suggesting that targeting this pathway may inhibit the growth and development of AML.
“The greatest potential of this study is the suppression of relapse of leukemia with a drug that inhibits beta-catenin,” says Scott Armstrong, MD, PhD, Division of Children pediatric hematology / oncology and lead author of the study.
A combination of two drugs destroys precancerous polyps in the colon without effects on normal tissues, thus opening a new avenue for chemoprevention of colon cancer, a team of scientists from the University of Texas MD Anderson Cancer Center Report in editing advanced online edition of Nature. The scheme, so far tested in mouse models and tissues of human colon cancer in the laboratory, appears to be a problem with chemopreventive agents – must be taken long term remains effective, expose patients to potential side effects, said Xiangwei lead author Wu, Ph.D., associate professor in MD Anderson Department of Head and Neck Surgery.
“This combination can be short term and periodically to provide long term, which would be a new approach to chemotherapy,” said Wu
The team found that combining vitamin A acetate (RAC) and Camino, the absence of tumor necrosis factor apoptosis inducing ligand to kill pre-cancerous polyps and inhibits tumor growth in mice that are deficient in a tumor suppressor gene. This gene, adenomatous polyposis coli (APC) and its downstream signaling molecules, are mutated or deficient in 80 percent of all cancers of the colon of man, “said Wu.
People who drink more are also likely to eat less fruit and consume more calories from a combination of alcoholic beverages and foods high in unhealthy fats and added sugars, according to a new study by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), and the the US Department of Agriculture (USDA).The study of more than 15,000 adults in the United States found that increased alcoholic beverage consumption was associated with decreased diet quality. The article is in the April 2010 issue of the Journal of the American Dietetic Association.
“Heavy drinking and dietary factors have independently been associated with cardiovascular disease, certain cancers, and other chronic health problems,” said NIAAA Acting Director Kenneth R. Warren, PhD. “This finding raises questions about whether the combination of alcohol misuse and poor diet might interact to further increase health risks.”
Scientists have found a way to identify patients with breast cancer are likely to respond to a type of chemotherapy. The new test also predict that is unlikely to see the benefit of treatment and help save them from unnecessary side effects.
The results – presented by researchers at the European Cancer Conference in Spain – that doctors should be able to tailor treatment to patients who will benefit and avoid the administration of toxic drugs for those not rescued.
In conducting a review of four large studies of breast cancer, researchers have discovered an abnormality on chromosome 17, called CEP17 is an indicator of “very important” that the tumor response to chemotherapy with anthracyclines call.